Is Arcosa (ACA) a Solid Growth Stock? 3 Reasons to Think "Yes"
Arcosa (ACA) possesses solid growth attributes, which could help it handily outperform the market.
Arcosa, Inc. (ACA) Q3 2025 Earnings Call Transcript
Arcosa, Inc. ( ACA ) Q3 2025 Earnings Call October 31, 2025 8:30 AM EDT Company Participants Erin Drabek - VP of Investor Relations Antonio Carrillo - President, CEO & Director Gail Peck - Chief Financial Officer Conference Call Participants Trey Grooms - Stephens Inc., Research Division Julio Romero - Sidoti & Company, LLC Ian Zaffino - Oppenheimer & Co. Inc., Research Division Jean Paul Ramirez - D.A. Davidson & Co., Research Division Garik Shmois - Loop Capital Markets LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Arcosa Third Quarter 2025 Earnings Conference Call.
Arcosa (ACA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Arcosa (ACA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Arcosa (ACA) Q3 Earnings and Revenues Beat Estimates
Arcosa (ACA) came out with quarterly earnings of $1.56 per share, beating the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $0.91 per share a year ago.
Arcosa (ACA) Reports Next Week: Wall Street Expects Earnings Growth
Arcosa (ACA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Building Product Stocks to Buy Despite Industry Challenges
Tariffs, inflation and housing headwinds weigh on the industry. Yet, AWI, FTDR, ACA and ECG look primed to benefit from infrastructure and innovation tailwinds.
Oscar Health: Undervalued, But Not Without Risk
Oscar Health is deeply undervalued but faces high short-term uncertainty due to ACA-specific risks and sector-wide negative catalysts. The expiration of ACA subsidies, adverse selection, and new legislation threaten enrollment and profitability, making Oscar more vulnerable than diversified peers. Despite near-term headwinds, Oscar is uniquely positioned for long-term growth, especially if ICHRA adoption improves the ACA risk pool.
Arcosa, Inc. (ACA) Q2 2025 Earnings Call Transcript
Arcosa, Inc. (NYSE:ACA ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Antonio Carrillo - President, CEO & Director Erin Drabek - VP of Investor Relations Gail M. Peck - Chief Financial Officer Conference Call Participants Brent Edward Thielman - D.A.
Arcosa (ACA) Surpasses Q2 Earnings Estimates
Arcosa (ACA) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $0.91 per share a year ago.
Top Wind Energy Stocks That Will Drive Long-Term Portfolio Growth
Wind power surges as U.S. demand grows-stocks like DTE, BEP, ACA and D eye big gains amid tech-driven energy shifts.
Arcosa (ACA) Upgraded to Strong Buy: Here's Why
Arcosa (ACA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Arcosa (ACA) is an Incredible Growth Stock: 3 Reasons Why
Arcosa (ACA) could produce exceptional returns because of its solid growth attributes.
